Retension Pharmaceuticals, Inc.
Retension Pharmaceuticals, a clinical-stage biopharma developing the PDE-5 inhibitor RTN-001 for hypertension, filed Amendment No. 1 to its S-1 for an IPO of 3,300,000 shares at an anticipated $11.00–$13.00 per share, seeking a Nasdaq Capital Market listing under "RTSN." The prospectus discloses that FY2025 consolidated financials were restated to correct an error and flags a material weakness in internal control over financial reporting. Underwriters are Leerink Partners, Guggenheim Securities, Oppenheimer & Co., and Titan Partners, with a 30-day option for 495,000 additional shares.
- Offering 3,300,000 shares at $11.00–$13.00 per share, listing on Nasdaq as "RTSN"
- Underwriters hold a 30-day option for 495,000 additional shares
- FY2025 consolidated financials restated; material weakness in internal control over financial reporting identified
- RTN-001 Phase 2b trial initiated October 2025; initial data expected first half of 2027
- RTN-001 administered to 243 participants across nine completed clinical trials
Price data unavailable.
A hypertension-focused biotech is going public while simultaneously disclosing a financial restatement and material weakness, pairing a large-market thesis with a governance red flag.
Targets a large hypertension market — an estimated 120 million U.S. adults — where first-generation PDE-5 inhibitors failed to achieve meaningful blood-pressure reduction, leaving an unmet need in uncontrolled and resistant hypertension.
The prospectus discloses a restatement of FY2025 financials and a material weakness in internal control over financial reporting, a notable governance red flag for a pre-revenue clinical-stage issuer. RTN-001 remains unapproved with no commercial products.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.